Related Experiment Video

Updated: Mar 29, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Hepatitis C virus: A global view

Amal Ahmed Mohamed1, Tamer A Elbedewy1, Magdy El-Serafy1

  • 1Amal Ahmed Mohamed, Biochemistry Department, National Hepatology and Tropical Medicine Institute, Cairo 11796, Egypt.

World Journal of Hepatology
|November 27, 2015
PubMed

Insights

Hepatitis C virus (HCV) infection affects millions globally, leading to severe liver disease. New direct-acting antivirals, like sofosbuvir, offer effective, peginterferon-free treatment options, improving patient outcomes.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) poses a significant global health burden, infecting 130-175 million people.
  • Chronic HCV infection is a leading cause of liver cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease.
  • Current management focuses on preventing liver complications and treating extrahepatic manifestations.

Purpose of the Study:

  • To review the advancements in Hepatitis C virus (HCV) treatment.
  • To highlight the shift from peginterferon-based therapies to direct-acting antivirals (DAAs).
  • To introduce sofosbuvir as a key component in peginterferon-free regimens.

Main Methods:

  • Literature review of recent studies on HCV treatment modalities.
  • Analysis of the efficacy and safety profiles of direct-acting antivirals.
  • Examination of clinical trial data for peginterferon-free regimens.

Main Results:

  • Peginterferon-based treatments are associated with numerous side effects, limiting accessibility.
  • Direct-acting antivirals represent a significant therapeutic advancement for chronic HCV.
  • Sofosbuvir is a pioneering compound enabling effective peginterferon-free combination therapies.

Conclusions:

  • The development of DAAs has revolutionized HCV management.
  • Peginterferon-free regimens, including sofosbuvir, offer improved treatment options with better tolerability.
  • Continued research into novel antiviral strategies is crucial for global HCV eradication.

Keywords:
Direct-acting antiviralsHepatitis CPeginterferonSofosbuvir

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.4K
Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis10:23

Lipid Droplet Isolation for Quantitative Mass Spectrometry Analysis

Published on: April 17, 2017

10.8K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
37
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
24
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable...
52
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Cystic Fibrosis: Pathogenesis01:23

Cystic Fibrosis: Pathogenesis

Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
1.0K
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
7.8K